Teva in talks to buy Allergan big generic-drug unit: WSJ

Sat Jul 25, 2015 6:25pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Reuters) - Israeli drug maker Teva Pharmaceutical Industries Ltd (TEVA.TA: Quote) is in talks to combine with Allergan Plc's (AGN.N: Quote) big generic-drug business, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, one of the people said, according to the Journal. The Allergan unit would be spun off and combined with Teva, which has a market value of $60 billion, this person told the newspaper.

(Reporting by Eric Beech in Washington; Editing by Bernard Or)

 
Teva Pharmaceutical Industries' Jerusalem oral solid dosage plant (OSD) is seen December 21, 2011. REUTERS/Ronen Zvulun